(Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROV	AL
OMB Number:	3235-0287
Estimated average burd	len
hours per response	0.5

5. Relationship of Reporting Person(s) to Issuer

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *- CARUSO JAMES V					2. Issuer Name and Ticker or Trading Symbol Cellectar Biosciences, Inc. [CLRB]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)XDirector10% Owner					
(Last) (First) (Middle) C/O CELLECTAR BIOSCIENCES, INC.,, 100 CAMPUS DRIVE					3. Date of Earliest Transaction (Month/Day/Year) 01/25/2022							X	X Officer (give title below) Other (specify below) President and CEO					
(Street) FLORHAM PARK, NJ 07932				4. If A	4. If Amendment, Date Original Filed(Month/Day/Year)							_X_	6. Individual or Joint/Group FilingCheck Applicable Line) _X_Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(Ci	ty)	(State)	(Zip)		Table I - Non-Derivative Securities Acqui								ired, Disposed of, or Beneficially Owned					
1.Title of S (Instr. 3)	Security	2. Ti Date (Mo		Execution Date, if Cod			•		4. Securities Acqu (A) or Disposed o (Instr. 3, 4 and 5)		Owned Following Transaction(s) (Instr. 3 and 4)		urities Beneficially g Reported		wnership orm:	eneficial wnership		
							Coc	le '	V A	`		rice				nstr. 4)		
			Table			ve Securities		this cur	s forr rrentl Dispo	m are not y valid Ol sed of, or E	require MB cont Beneficia	d to res trol nur ally Own	spond unles nber.		contained i displays a	n SEC 14	74 (9-02)	
1. Title of Derivative Security (Instr. 3)	Conversion	ercise (Month/Day/Year) of ative	e Execution Date, if T	4. Transac Code	4. 5. Number of β Cransaction Derivative Securities (6. Dat Expira	6. Date Exercisable and 7. Expiration Date U			7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	Ownership Form of Derivative Security: Direct (D) or Indirect	Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exerci	isable	Expiration Date	Titl	le	Amount or Number of Shares		(Instr. 4)	(Instr. 4)		
Stock option (right to buy)	\$ 0.55	01/25/2022		A		1,419,000		((1)	01/25/20	13/1	ommon Stock	1,419,000	\$ 0	1,419,000	D		

Reporting Owners

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
CARUSO JAMES V C/O CELLECTAR BIOSCIENCES, INC., 100 CAMPUS DRIVE FLORHAM PARK, NJ 07932	X		President and CEO					

Signatures

/s/ Christina Blakley, attorney-in-fact for James V. Caruso	01/27/2022
-*Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- This option shall vest over a period of three years from the grant date, with 1/3 vesting on the first anniversary of the grant date and the remainder vesting in 24 equal monthly installments over a 24 month period beginning on the first anniversary of the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.